Search
Avalo Therapeutics Inc
AVTXAdd to Watchlist
18.840USD
+1.550+8.96%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
464.18MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+8.96%
5 Days
+3.52%
1 Month
+38.43%
6 Months
+10.69%
Year to Date
+3.74%
1 Year
+279.84%
Key Figures
17.450Open
18.965High
1.82MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
7.37%Turnover Ratio
17.290Prev. Close
17.270Low
24.06MTurnover
LossP/E Static
6.79P/B
0.00%Div Yield TTM
-71.09%ROA
24.27052wk High
0.94Volume Ratio
-35.13MNet Profit
24.64MShares
-5.5639EPS TTM
0.84Beta
-88.76%ROE
3.58052wk Low
9.80%Amplitude
100.00%Gross Margin
464.18MMarket Cap
5.31Reward/Risk
5.09%Risk Rate
TradingKey Stock Score of Avalo Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Avalo Therapeutics Inc's fundamentals are relatively stable, and its growth potential is good.Its valuation is considered fairly valued, ranking 117 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 46.18.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Avalo Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Avalo Therapeutics Inc Highlights
StrengthsRisks
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Growing
The company is in a growing phase, with the latest annual income totaling USD 59.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 59.00K.
Undervalued
The company’s latest PE is -3.39, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 24.87M shares, increasing 21.84% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 866.37K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 3.71.
Analyst Rating
Based on
14
analysts
Strong Buy
Current Rating
46.182
Target Price
+167.10%
Upside Space
Avalo Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Avalo Therapeutics Inc Info
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Ticker SymbolAVTX
CompanyAvalo Therapeutics Inc
CEONeil (Garry A)
Websitehttps://www.avalotx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Avalo Therapeutics Inc (AVTX)?
The current price of Avalo Therapeutics Inc (AVTX) is 18.84.
What is the symbol of Avalo Therapeutics Inc?
The ticker symbol of Avalo Therapeutics Inc is AVTX.
What is the 52-week high of Avalo Therapeutics Inc?
The 52-week high of Avalo Therapeutics Inc is 24.27.
What is the 52-week low of Avalo Therapeutics Inc?
The 52-week low of Avalo Therapeutics Inc is 3.58.
What is the market capitalization of Avalo Therapeutics Inc?
The market capitalization of Avalo Therapeutics Inc is 464.18M.
Is Avalo Therapeutics Inc (AVTX) currently rated as Buy, Hold, or Sell?
According to analysts, Avalo Therapeutics Inc (AVTX) has an overall rating of STRONG BUY, with a price target of 46.18.
What is the Earnings Per Share (EPS TTM) of Avalo Therapeutics Inc (AVTX)?
The Earnings Per Share (EPS TTM) of Avalo Therapeutics Inc (AVTX) is -5.84.